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Abstract
Background: Semaphorins act as chemotactic cues for cell movement via their transmembrane receptors, plexins.
Somatic missense mutations in the plexinB1 gene coupled with overexpression of the protein frequently occur in
prostate tumours, indicating a role for plexinB1 in the pathogenesis of prostate cancer.
Results: Two specific mutations found in prostate cancer enhance RhoD binding and one other mutation results
in loss of inhibition of Rac-dependent Pak1 phosphorylation and lamellipodia formation and in impairment of
trafficking of plexinB1 to the membrane. None of the three characterised mutations affect PDZRhoGEF binding,
RhoA activity, the interaction of plexinB1with the oncogenes ErbB2 or c-Met or ErbB2 phosphorylation. The
mutations have the net effect of increasing cell motility by blocking plexinB1-mediated inhibition of Rac while
enhancing the interaction with RhoD, an anti-migratory factor.
Conclusions: PlexinB1 mutations block plexinB1-mediated signalling pathways that inhibit cell motility.
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Background
Semaphorins are a group of 20 or more secreted or
membrane bound proteins [1] that act as chemotactic
cues for cells expressing their transmembrane receptors
plexins [2]. Semaphorins affect cell behaviour in diverse
ways, regulating cell motility [3], invasive capacity [4],
adhesion [5] and cell and axon growth cone collapse [6].
Semaphorins consequently have a function in many phy-
siological processes including angiogenesis [7], cell
migration [8,9], immune regulation [10] and organogen-
esis, affecting nervous system [11,12], lung [13], kidney
[14] and cardiovascular development [15,16] and epithe-
lial-mesenchymal interactions [14]. The response of a
cell to semaphorin stimulation depends on the type of
responding cell and particular semaphorins can generate
opposite reactions depending on cell type [17]. The
transmembrane semaphorin receptors, plexins, either
bind semaphorins directly, or in the case of most class 3
semaphorins, to a complex of neuropilins and plexins
[2,18]. Semaphorin 4D (Sema4D) binds directly to its
receptor, plexinB1 [2].
Semaphorin/plexin signalling results in activation of
receptor tyrosine kinases and modulation of the actin
cytoskeleton via regulation of several specific small
RhoGTPases. PlexinB1 binds to RacGTP [19,20], seques-
tering it from its downstream effectors, such as Pak1
[21], and to Rnd [22] and RhoD [23]. Rac, Rnd and RhoD
all bind to the same region in the cytoplasmic domain of
plexinB1, the RhoGTPase binding domain (RBD) [23].
Rnd binding is required for the binding of R-Ras to plex-
inB1 and for the R-RasGTPase activating protein (GAP)
activity of plexinB1 which inactivates R-Ras resulting in a
decrease in integrin and PI3K activation [24,25].
Sema4D/plexinB1 signalling activates RhoA through acti-
vation of PDZRhoGEF and LARG which bind to the C-
terminal of the plexinB1 protein [26]. PlexinB1 can also
mediate the inhibition of RhoA via the recruitment of
p190RhoGAP [27]. PlexinB1 interacts with the receptor
tyrosine kinases c-Met [28] and ErbB2 [29] via their
extracellular domains and Sema4D/plexinB1 signalling
results in c-Met and ErbB2 phosphorylation [28,29].
Activated ErbB2 phosphorylates tyrosines on plexinB1
creating a binding site for PLCg. PLCg binding is required
for Sema4D-mediated RhoA activation [30]. Sema4D can
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plexinB1 co-receptors expressed [31].
Crystal structures of the RBD [23] and of the cytoplas-
mic domain of plexinB1 in complex with Rac1 [32,33]
have been determined. Bell et al. [33]., identified a sec-
ond RhoGTPase binding site in addition to the RBD,
adjacent to the Ras site, which stabilises a trimeric
structure of plexinB1-Rac complexes.
We have previously found mutations in the plexinB1
gene in 8/9 prostate cancer bone metastases, 7/17 pros-
tate cancer lymph node metastases and 41/89 primary
cancers, together with overexpression of the protein
[34]. The mutations in plexinB1 enhance adhesion,
migration and invasion in vitro and inhibit cell collapse
[34]. The finding of functionally significant mutations in
plexinB1 in prostate tumours and overexpression of the
plexinB1 protein suggests that plexinB1 has a role in
prostate cancer and so is a potential target for therapy.
However, the mechanism by which plexinB1 contributes
to prostate cancer progression is yet to be determined.
Results
Mutations in plexinB1 increase RhoD binding
RhoD binds to the RBD domain of plexinB1 in the region
where mutations are found in prostate cancer [35]. To
determine if the mutations affect binding of RhoD to plex-
inB1 we performed GST pull down assays using GST-
cyto-plexinB1(wild type (WT) or mutant) fusion proteins
and dominant negative (T31K) or constitutively active
(G26V) RhoD. Three mutations were characterised in
these experiments: A5359G (amino acid change T1697A),
A5653G (amino acid change T1795A) and T5714C
(amino acid change L1815P). Constitutively active RhoD
(G26V) bound to the cytoplasmic domain of WT plex-
inB1, but dominant negative RhoD(T31K) did not (Figure
1). Binding of RhoDGTP to plexinB1 was not inhibited by
the mutations in plexinB1. The interaction was enhanced
by the presence of mutations A5359G (T1697A) and
A5653G (T1795A) in the cytoplasmic domain of plexinB1
(Figure 1). To test the effect of RhoDGTP expression on
plexinB1 function, we performed collapse assays on COS-
7 cells co-transfected with plexinB1, Rnd, and RhoD
(G26V) or RhoD(T31K). Expression of constitutively active
RhoD significantly reduced cell collapse (Figure 1C).
Mutation of plexinB1 results in loss of inhibition of
RacL61-dependent Pak1 phosphorylation
PlexinB1 on the plasma membrane binds to and seques-
ters Rac-GTP and inhibits it from activating down-
stream effectors such as p21-activated kinase1 (Pak1)
[21]. We have previously found that binding of Rac1 to
the cytoplasmic domain of plexinB1 is inhibited by
L1815P and is diminished by T1795A and T1697A
amino acid changes [34]. To test the effect of cancer-
associated mutations of plexinB1 on Rac-dependent
Pak1 phosphorylation, WT plexinB1 or three different
mutant forms of the protein were co-expressed with
RacL61 and Pak1 in COS-7 cells. The phosphorylation
status of Pak1 was monitored by western blotting using
anti-phospho199/204-Pak1 antibody. As previously
reported [36] coexpression of Rac1L61 and Pak1 stimu-
lated the autophosphorylation of Pak1 (Figure 2A). Co-
expression of WT plexinB1 with Rac1L61 and Pak1
inhibited Pak1phosphorylation. In contrast co-expres-
sion of plexinB1 (T1795A) or plexinB1 (L1815P) with
Rac1L61 and Pak1 did not inhibit Pak1 phosphorylation.
PlexinB1 (T1697A) inhibited Rac-dependent Pak1 phos-
phorylation to a similar extent as WT. Therefore the
T5714C(L1815P) and A5653G (T1795A) mutations in
plexinB1 result in loss of plexinB1-mediated inhibition
of Rac-dependent Pak1 phosphorylation.
Mutation of plexinB1 results in loss of inhibition of
RacL61-dependent cell spreading
Cell spreading and extension of lamellipodia are pheno-
types characteristic of Rac1 activation. COS-7 cells
Figure 1 Mutation of plexinB1 enhances RhoD binding. A).GST-
cyto-plexinB1 (WT and mutant) fusion proteins were used in GST
pulldown assays with lysates of HEK293 cells expressing
constitutively active (G26V) or dominant negative (T31K) RhoD-myc.
B). Input of RhoD(G26V)-myc, RhoD(T31K)-myc and WT and mutant
GST-cyto-plexinB1 fusion proteins. C). Expression of RhoDGTP
decreases cell collapse. COS-7 cells co-transfected with plexinB1,
Rnd and RhoD(G26V)-myc, or RhoD(T31K)-myc were stimulated with
sema4D for 5mins, fixed and stained for plexinB1 (FITC) and myc
(TRITC) and the % cell collapse scored. i).% cell collapse +/- SE, * p
< 0.001 versus RhoD(T31K) 2 tailed ttest. ii) representative non-
collapsed cell. iii) representative collapsed cell.
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Page 2 of 9Figure 2 The effect of plexinB1 mutations on Rac signalling. A). Mutation of plexinB1 impairs inhibition of Pak1 phosphorylation. The
phosphorylation status of Pak1 in COS-7 cells transfected with plexinB1 (WT or mutant), RacL61 and Pak1 was monitored by western blotting
using anti- phospho199/204-Pak1 antibody. B). Mutation of plexinB1 impairs inhibition of cell spreading. COS-7 cells transfected with RacL61 and
plexinB1 (WT or mutants) were plated on fibronectin for 2 h and those with a large surface area and discernible lamellipodia (’spread’
phenotype) scored. Bars represent means +/- SE, *p < 0.05 versus RacL61 + WT, one tail t-test. C). Mutation in plexinB1 inhibits Rac-dependent
trafficking of plexinB1 to the cell surface. COS-7 cells co-transfected with plexinB1 (WT or mutant) and RacL61 were treated with Sema4D-AP
fusion protein and cell surface binding of Sema4D-AP assessed. i). Sema4D-AP cell surface binding detected with BCIP/NBT solution,
representative of 3 independent experiments, ii). Western blot to show expression of VSV-plexinB1 and myc-RacL61 in transfected cells. iii).
Bound alkaline phosphatase activity in transfected cells. Bars represent means +/- SE. *p < 0.01 versus vector without RacL61; **p < 0.01 versus
WT with RacL61, one tail t-test. D). Mutation of plexinB1 does not affect Sema4D binding. HEK293T cells were cotransfected with VSV-plexinB1
(WT or mutant) and Sema4D-Fc. The plexinB1 protein in the cell lysate was immunoprecipitated with anti-Fc antibody.
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with a large surface area and discernible lamellipodia 2
h after plating on fibronectin (Figure 2B). Expression of
WT plexinB1 reduced the number of cells showing this
phenotype, consistent with the binding and sequestra-
tion of RacGTP by plexinB1, which effectively prevents
Rac1 from participating in other signaling pathways.
The inhibitory effect on cell spreading was retained in
cells expressing plexinB1 (T1697A) and (T1795A). In
contrast, the inhibitory effect on cell spreading was lost
in cells expressing plexinB1 (L1815P).
Mutation of plexinB1 inhibits Rac-dependent trafficking
of plexinB1 to the cell surface
Rac1-GTP binds to and facilitates the cell surface
expression of plexinB1 [21]. We sought to determine if
mutation of plexinB1 affects Rac-dependent cell surface
trafficking of plexinB1.
COS-7 cells co-transfected with plexinB1 (WT or
mutant) and RacL61 were treated with Sema4D-AP
fusion protein and cell surface binding of Sema4D-AP
assessed. In the absence of RacL61 co-expression, COS-
7 cells expressing WT or three mutant forms of plex-
inB1 showed similar levels of Sema4D-AP cell surface
binding, significantly higher than cells not transfected
with plexinB1 (p < 0.01) (Figure 2C). Sema4D-AP cell
surface binding was enhanced when RacL61 was co-
expressed with WT plexinB1. Similarly, cell surface
binding of Sema4D-AP to COS-7 cells was enhanced
when RacL61 was co-expressed with plexinB1(T1697A)
and plexinB1(T1795A) to a similar extent as WT. In
contrast, co-expression of RacL61 with plexinB1
(L1815P), did not enhance cell surface binding of
Sema4D-AP. A significant difference in staining intensity
was observed between cells expressing WT and plexinB1
(L1815P) in the presence of Rac1L61 (p <0 . 0 1 )b u tn o t
in the absence of Rac1L61. As the Sema4D binding
capacity of plexinB1 was not affected by the mutations
(as shown by immunoprecipitation, Figure 2D), our
results show that the L1815P change inhibits Rac-
dependent trafficking of plexinB1 to the cell surface.
Taken together, these results show that the T5714C
(L1815P) mutation renders plexinB1 defective in seques-
tering and inhibiting Rac1 function and in facilitating
plexinB1 trafficking. The A5653G (T1795A) mutation,
which reduces RacGTP binding, also failed to inhibit
Pak1 activation, although no discernible effect on cell
spread or trafficking was seen.
Effect of mutations on RhoA activation
PlexinB1 binds to the RhoGEFs, PDZRhoGEF and LARG,
resulting in activation of RhoA. We investigated whether
the mutations affect the interaction between PDZRhoGEF
and plexinB1 and plexinB1-mediated Rho activation.
Immunoprecipitation of PDZRhoGEF with anti-VSV from
lysates of HEK293 cells co-expressing PDZRhoGEF and
VSV-plexinB1 indicated that the mutations have little
effect on PDZRhoGEF binding to plexinB1 (Figure 3A).
Rho activation assays, using rhotekin pull down which
binds to active RhoGTP selectively, showed that mutant
forms of plexinB1 activate Rho to a similar extent as the
WT form of plexinB1(Figure 3B). Expression of exogenous
plexinB1 (WT or mutant) resulted in Rho activation in
both the presence and absence of Sema4D, showing that
overexpression of the plexinB1 receptor can mimic ligand
binding as shown before [28]. Therefore the mutations do
not affect plexinB1-mediated Rho activation.
PlexinB1 can also inhibit Rho activation via its interac-
tion with p190RhoGAP [27]. Expression of WT plex-
inB1 inhibits the formation of stress fibres (an indicator
of Rho activity) in COS-7 cells (Figure 3C), suggesting
that RhoA is inhibited by plexinB1 in these cells, possi-
bly via p190RhoGEF. The ability of three plexinB1
mutants to inhibit stress fibre formation was not signifi-
cantly different from that of WT (Figure 3D). Taken
together we saw no evidence that the three mutant
forms of plexinB1 tested affect RhoA signalling.
Effect of mutations on the interaction of ErbB2 and c-met
with plexinB1 and on plexinB1-mediated phosphorylation
of ErbB2
PlexinB1 interacts with and activates the receptor tyro-
sine kinases ErbB2 [29] and c-Met [28] and Sema4D sti-
mulation results in phosphorylation of both proteins in
transfected HEK293 cells [31]. To determine if mutations
of plexinB1 affect the interaction of plexinB1 with ErbB2,
HEK293 cells were co-transfected with VSV-plexinB1
(WT or mutant) and ErbB2. ErbB2 was co- immunopre-
cipitated with anti-VSV (Figure 4A). Both WT and
mutant forms of plexinB1 interacted with ErbB2 and the
strength of interaction between the different mutant
forms of plexinB1 and the WT form were comparable.
Similarly, all mutant forms of plexinB1 tested bound to
c-Met to an equivalent extent as WT plexinB1 in cells
co-expressing VSV-plexinB1 (WT or mutant) and c-Met
(Figure 4B). WT and mutant forms of plexinB1 pulled
down the 170 kDa extracellular form of c-Met indicating
that different forms of plexinB1 interact with the extra-
cellular domain of c-Met. Therefore mutations in plex-
inB1 do not affect the interaction of plexinB1 with ErbB2
or c-Met. Exogenous expression of WT plexinB1
increased phosphorylation of ErbB2 (Figure 4C), and the
mutations had little effect on this process.
Discussion
Mutations in the gene for plexinB1 are frequent in pros-
tate cancer and the plexinB1 protein is overexpressed in
prostate tumours, indicating that plexinB1 has a role in
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the mechanism by which mutation of plexinB1 contri-
butes to prostate cancer progression. The three different
cancer-associated plexinB1 mutations that were investi-
gated in this study affect plexinB1-small RhoGTPase sig-
nalling in different ways, but have no effect on ErbB2, c-
Met binding or RhoA activity.
Surprisingly, in spite of its position in the RBD region
of plexinB1, the L1815P change does not impair RhoD
binding. Rac has been shown to bind to a second site
close to the R-Ras binding site in the cytoplasmic
domain of plexinB1, in addition to the RBD site [33]. It
is possible that RhoD also binds to this second site (site
B in reference [33]) so that mutations in the RBD would
not prevent RhoD binding. Alternatively the mode of
binding of RhoD to the RBD may be different from that
of the Rnd1 and Rac1. In an analogous way, the L1815P
change inhibits Rnd1 binding to the RBD but not Rnd2
Figure 3 Effect of plexinB1 mutation on RhoA activation. A). Mutation of plexinB1 does not affect PDZRhoGEF (PRG) binding. Lysates of
HEK293 cells co-expressing VSV-plexinB1 and PDZRhoGEF were immunoprecipitated with anti-VSV and bound proteins detected by western
blotting. B). Mutation of plexinB1 does not affect RhoA activation. Lysates of HEK293 cells co-expressing VSV-plexinB1, FLAG-PDZRhoGEF and
myc-RhoA were immunoprecipitated with GST-Rhotekin and RhoGTP detected by western blotting with anti-myc. C). COS-7 cells seeded onto
coverslips were either transfected with plexinB1 (iii and iv) or vector (i and ii). Fixed cells were stained with anti-plexinB1 (ii and iv) or for actin (i
and iii). Panel i and ii, and iii and iv, show the same field. Scale bar = 20 μm. D). The number of cells possessing more than three straight actin
bundles of at least 5 μm long was counted and expressed as a percentage of the total number of cells in the field. Bars represent means +/- SE.
D). Sema4D in conditioned medium. Conditioned medium was collected from Cos7 cells transfected with vector or Sema4D-Fc and the protein
detected by immunoblotting with anti-Sema4D antibody.
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retained by the T1795A and T1697A mutant forms, and
binding is enhanced by these mutations. The T1795A
amino acid change occurs within the RBD region and
the T1697A change occurs outside of this region [35].
All 3 mutant forms have lost R-RasGAP activity, yet
only the L1815P mutation inhibits Rnd binding. Loss of
Rnd1 binding would account for the loss of R-RasGAP
activity in the L1815P mutant form, since R-RasGAP
activity is dependent on Rnd binding [24]. In contrast,
the T1795A and T1697A forms bind Rnd, yet R-Ras-
GAP activity is lost. Interestingly, RhoD has been shown
to antagonise Rnd in signalling via plexinA1 [38]. We
have found that RhoDGTP reduced cell collapse when
co-expressed with Rnd and plexinB1. If RhoD does
antagonise Rnd signalling via plexinB1, the increase in
RhoD binding seen in the T1795A and T1697A mutant
forms may contribute to the loss of R-Ras GAP activity
seen for these forms.
RhoDGTP inhibits stress fibre formation and motility
[39]. Binding of RhoDGTP to WT plexinB1 may sequester
RhoD from downstream signalling partners. Expression of
the T1697A and T1795A mutant forms of plexinB1 in
tumour cells is predicted to have the effect of releasing the
cell from the inhibitory effect of RhoD on motility and
stress fibre formation, thereby promoting motility.
RacGTP binds and activates the autophosphorylation
of Pak1 [36]. WT plexinB1 binds and sequesters
RacGTP and thereby inhibits Pak1 phosphorylation [21].
Phosphorylation of Pak1 is not however inhibited by co-
expression of RacGTP with the L1815P or T1795A
mutant forms of plexinB1. The L1815P sequence change
inhibits Rac, Rnd and R-Ras binding and the intrinsic R-
RasGAP activity of plexinB1 [34]. The T1795A mutation
does not affect Rnd binding but reduces Rac binding
and inhibits R-Ras binding and R-RasGAP activity [34].
The release of inhibition of Pak1 phosphorylation by
tumour cells expressing the L1815P and T1795A mutant
forms of plexinB1is expected to result in an increase in
MAPK signalling and to promote tumour progression.
Activation of Rac results in reorganisation of the actin
cytoskeleton to form lamellipodia at the leading edge of
migrating cells, a phenotype that is inhibited by WT
plexinB1 expression. The L1815P mutation in plexinB1
blocks this inhibition of lamellipodia formation. The
release from lamellipodia inhibition is expected to result
in an increase in motility, and is consistent with the
increase in motility we have observed in cells expressing
this mutant form of plexinB1 [34]. We have previously
shown that overexpression of the three characterised
mutations in HEK293 cells, without exogenous RacL61
expression, resulted in an increase in cell spreading
above that of vector controls [34]. These results suggest
that in addition to the loss of inhibition of Rac function
shown here, the mutations confer a gain of function
which results in an increase in cell spreading.
Rac has also been shown to act upstream of plexinB1
facilitating the trafficking of plexinB1 to the cell mem-
brane. Cells expressing the L1815P mutated form of
plexinB1 show a decrease in cell surface expression of
the protein.
Conclusions
Activated plexinB1 functions either as a positive or
negative regulator of several signalling pathways that
promote cell migration. ErbB2, c-Met and RhoA are
activated by plexinB1, enhancing cell migration. In con-
trast, Rac, Rnd and R-Ras are inhibited by plexinB1,
resulting in a decrease in cell motility. The response of
a cell to plexinB1 activation depends on a balance
Figure 4 Mutation of plexinB1 does not affect interaction of
plexinB1 with ErbB2 or c-Met. Lysates of HEK293 cells co-
expressing ErbB2(A) or c-Met (B) and VSV-plexinB1 (WT or mutant)
were immunoprecipitated with anti-VSV and bound proteins
detected with anti-ErbB2 (A) or anti c-Met (B). Representative of 3
independent experiments. C). HEK293 cells transfected with plexinB1
(WT or mutant) or vector were treated with control or sema4D
conditioned medium or with EGF(500 ng/ml) for 20 mins and the
phosphorylation of ErbB2 detected by immunoblotting.
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identified have no effect on ErbB2, c-Met or PDZRho-
GEF binding or RhoA activity which enhance migration,
but one or more of the mutations inhibit or hinder Rac,
Rnd, and R-Ras binding and R-RasGAP [34] activity.
The mutations thus have the net effect of increasing cell
motility by the loss of inhibitory pathways. Two of the
mutations also promote sequestration of RhoDGTP, an
anti-migration factor.
Methods
Plasmid constructs and cell culture
The expression constructs for VSV-plexinB1and
Sema4D-AP were kind gifts from Dr. L. Tamagnone.
The region on plexinB1 cDNA encoding the intracellu-
lar domain (amino acids 1512-2135, accession no.
X87904) was amplified by PCR and cloned into pGEX-4
T-3 (Amersham) using SalI and XhoI sites to produce
pGEXB1cytoWT. The prostate cancer-associated muta-
tions: L1815P, T1795A and T1697A were introduced
into pGEXB1cytoWT and into VSV-plexinB1 by using
QuikChange II XL in vitro mutagenesis kit (Stratagene).
Other constructs were kindly provided by the following:
Dr. KL Guan, pRK5-mycRacL61 and N17; Professor
Takeshi Endo (Chiba University, Japan): RhoD pEF-
BOS/Myc-RhoD G26V and T31K; Dr. Hitoshi Kikutani
(Osaka University, Japan): Sema4D-Fc; Dr. J. Swiercz
(Heidelburg): FLAG-PDZRhoGEF, ErbB2, RhoA; Dr M.
Driessens: myc-PDZRhoGEF; Prof. J.Chernoff (Fox
Chase Cancer Centre): pCMV-myc-hPak1. HEK293 and
COS-7 cells were grown in DMEM (10% FCS).
Antibodies
The following antibodies were used: anti-VSV, anti-FLAG,
anti-myc (Sigma, V4888, F7425, C956), anti-Human IgG
Fc (Jackson ImmunoResearch, 109-005-098), anti-b-actin
(Abcam, ab6276), anti-Pak1 (Chemicon, AB3844), anti-P-
Pak, anti-phospho-ErbB2 (Cell Signalling), ErbB2 (Milli-
pore), Sema4D and plexinB1 (ECM Biosciences), c-Met
(c-28), plexinB1 (H300), (Santa Cruz).
Rac-mediated Pak1 phosphorylation
COS-7 cells were transfected with Pak1, constitutively
active Rac (RacL61), and plexinB1(WT or mutant) or
empty vector using Lipofectamine (Invitrogen). Lysates
were analysed for Pak phosphorylation using a phospho-
Pak1 antibody.
Recombinant Sema4D
COS-7 cells transfected with Sema4D-Fc or Sema4D-AP
or empty vector (control) were grown in serum free
medium for 72 h. The conditioned medium was col-
lected and used directly or purified. Sema4D concentra-
tion was assessed by western blotting (Figure 3).
Cell spread assays
COS-7 cells transfected with myc-RacL61 and VSV-
plexinB1 (WT or mutant) or vector were plated on 10
μg/ml fibronectin. Unattached cells were washed away
after 2 h. Attached cells were fixed (4% paraformalde-
hyde), permeabilized (0.1% Triton-X 100), blocked (2%
BSA) and subjected to immunofluorescence staining
(anti-myc). At least 200 myc-RacL61 positive cells were
scored per slide.
In situ binding of Sema4D-AP with plexinB1
COS-7 cells transfected with plexinB1 (WT or mutant)
and RacL61 or vector were washed with HBAH (Hanks
balanced salt solution with 20 mM HEPES pH 7.0, 0.5
mg/ml BSA, 0.1% (w/v) NaN3), treated with HBAH con-
taining 1,000 ng/ml Sema4D-AP for 90 min then
washed with ice-cold HBAH and fixed (65% (v/v) acet-
one, 8% (v/v) formalin, 20 mM HEPES pH 7.0). The
cells were incubated at 65°C for 100 min, then in BCIP/
NBT solution in the dark.
Immunoprecipitation
Lysates of HEK293 transfected cells were incubated with
1 μg of selective antibody for 2 h at 4°C. The antigen-
antibody complex was incubated with Protein-G sephar-
ose for 2 h, washed 3 times and analyzed by
immunoblotting.
GST-pull down assay
Lysates of COS-7 cells expressing RhoDG26V or
RhoDT31K were incubated with GST-fused cyto-plex-
inB1 (WT or mutant) overnight. Following washing of
the matrix, the samples were analysed by SDS-PAGE
and immunoblotting.
Collapse assay
COS-7 cells plated on coverslips were co-transfected
with plexinB1, Rnd and RhoDG26V-myc or RhoDT31K-
myc. 48 h post transfection, the cells were treated with
sema4D (4 μg/ml) for 5 mins, then fixed with 4% paraf-
ormaldehyde, permeabilised with 0.2% triton, then
stained by immunofluorescence using anti-plexinB1
antibody(R&D) (FITC secondary antibody(Southern Bio-
tech)) and anti-myc antibody (Abcam) (TRITC second-
ary). Co-transfected cells were sized using imageJ and
cells with a size of < 500 μm2 with 3 or more processes
were scored as ‘collapsed’. Cells were scored ‘blind’.T h e
experiment was performed 3× in triplicate with a total
of 186 or more co-transfected cells counted per
condition.
Rho activity assay
HEK293 cells were transfected with RhoA, PDZRhoGEF
and plexinB1 (WT or mutant) or vector control. 48 h
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Sema4D conditioned medium for 25 mins and the lysate
incubated with 50 μl Rhotekin (Upstate) for 1 h, washed
3 times and the pulled down protein analysed by wes-
tern blot with anti-myc antibody.
Stress fibre assay
COS-7 cells transfected with plexinB1 (WT or mutant)
were fixed (4% paraformaldehyde), permeabilized (0.1%
Triton-X 100), blocked with 2% BSA then subjected to
immunocytochemistry with anti-plexinB1 (SantaCruz)
then goat-anti-mouse FITC (SouthernBiotech) supple-
mented with Phalloidin-TRITC (Sigma). The number of
cells possessing more than three straight actin bundles
of at least 5 μm long was counted. The identities of the
slides counted were blinded to the researcher. At least
50 cells were counted per slide.
PlexinB1-mediated ErbB2 phosphorylation
HEK293 cells transfected with vector or plexinB1 (WT
or mutants) were serum starved over 2 nights then trea-
ted with control or sema4D conditioned medium or
rhEGF(500 ng/ml, R&D Biosytems) for 20 mins. Lysates
were analysed for ErbB2 phosphorylation using an anti
phospho-ErbB2 antibody.
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